Analysts Offer Insights on Healthcare Companies: Nektar Therapeutics (NASDAQ: NKTR), Kezar Life Sciences Inc (NASDAQ: KZR) and Lemaitre Vascular (NASDAQ: LMAT)

By Jason Carr

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Nektar Therapeutics (NKTRResearch Report), Kezar Life Sciences Inc (KZRResearch Report) and Lemaitre Vascular (LMATResearch Report) with bullish sentiments.

Nektar Therapeutics (NKTR)

William Blair analyst Andy Hsieh maintained a Buy rating on Nektar Therapeutics yesterday. The company’s shares closed yesterday at $34.03, close to its 52-week low of $29.22.

According to TipRanks.com, Hsieh is a 1-star analyst with an average return of -0.8% and a 42.1% success rate. Hsieh covers the Healthcare sector, focusing on stocks such as Viking Therapeutics, Seattle Genetics, and ImmunoGen.

Nektar Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $77.50, a 127.7% upside from current levels. In a report issued on June 2, Cowen & Co. also maintained a Buy rating on the stock with a $82 price target.

See today’s analyst top recommended stocks >>

Kezar Life Sciences Inc (KZR)

William Blair analyst Matt Phipps maintained a Buy rating on Kezar Life Sciences Inc today. The company’s shares closed yesterday at $9.81, close to its 52-week low of $8.61.

According to TipRanks.com, Phipps is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -23.4% and a 16.7% success rate. Phipps covers the Healthcare sector, focusing on stocks such as Autolus Therapeutics Plc, Atara Biotherapeutics, and Portola Pharma.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Kezar Life Sciences Inc.

Lemaitre Vascular (LMAT)

In a report released today, Michael Petusky from Barrington maintained a Buy rating on Lemaitre Vascular, with a price target of $32. The company’s shares closed yesterday at $26.56.

Petusky observed:

“We traveled with LeMaitre management last week as the company met with Barrington clients in Richmond, VA. This marked the second time in a month that we have spent time on the road with members of this management team and the messaging remains consistent and long-term bullish despite some short-term challenges.”

According to TipRanks.com, Petusky is a 3-star analyst with an average return of 2.8% and a 50.3% success rate. Petusky covers the Healthcare sector, focusing on stocks such as Anika Therapeutics Inc, Varian Medical Systems, and Merit Medical Systems.

Lemaitre Vascular has an analyst consensus of Moderate Buy, with a price target consensus of $32.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.